X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs GSK PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. GSK PHARMA FRESENIUS KABI ONCO./
GSK PHARMA
 
P/E (TTM) x 22.1 60.1 36.8% View Chart
P/BV x 3.1 11.8 26.4% View Chart
Dividend Yield % 0.0 2.1 -  

Financials

 FRESENIUS KABI ONCO.   GSK PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
GSK PHARMA
Mar-16
FRESENIUS KABI ONCO./
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1763,850 4.6%   
Low Rs792,966 2.6%   
Sales per share (Unadj.) Rs37.7332.3 11.3%  
Earnings per share (Unadj.) Rs5.144.3 11.5%  
Cash flow per share (Unadj.) Rs6.747.2 14.2%  
Dividends per share (Unadj.) Rs050.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs42.5202.7 21.0%  
Shares outstanding (eoy) m158.2384.70 186.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.410.3 32.9%   
Avg P/E ratio x25.076.9 32.5%  
P/CF ratio (eoy) x18.972.2 26.2%  
Price / Book Value ratio x3.016.8 17.8%  
Dividend payout %0112.9 0.0%   
Avg Mkt Cap Rs m20,135288,643 7.0%   
No. of employees `0001.24.6 25.0%   
Total wages/salary Rs m7034,434 15.9%   
Avg. sales/employee Rs Th5,176.26,104.5 84.8%   
Avg. wages/employee Rs Th610.4961.6 63.5%   
Avg. net profit/employee Rs Th699.6813.7 86.0%   
INCOME DATA
Net Sales Rs m5,96328,148 21.2%  
Other income Rs m181,218 1.5%   
Total revenues Rs m5,98129,366 20.4%   
Gross profit Rs m1,4304,774 30.0%  
Depreciation Rs m258248 104.0%   
Interest Rs m-260-   
Profit before tax Rs m1,2165,744 21.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-6826 -261.9%   
Tax Rs m3422,018 17.0%   
Profit after tax Rs m8063,752 21.5%  
Gross profit margin %24.017.0 141.4%  
Effective tax rate %28.135.1 80.1%   
Net profit margin %13.513.3 101.4%  
BALANCE SHEET DATA
Current assets Rs m5,10221,462 23.8%   
Current liabilities Rs m2,38510,536 22.6%   
Net working cap to sales %45.638.8 117.4%  
Current ratio x2.12.0 105.0%  
Inventory Days Days15068 221.8%  
Debtors Days Days11316 690.1%  
Net fixed assets Rs m5,1484,717 109.1%   
Share capital Rs m158847 18.7%   
"Free" reserves Rs m6,55616,308 40.2%   
Net worth Rs m6,73217,171 39.2%   
Long term debt Rs m95216 5,951.3%   
Total assets Rs m10,38830,620 33.9%  
Interest coverage x-45.8NM-  
Debt to equity ratio x0.10 15,180.4%  
Sales to assets ratio x0.60.9 62.4%   
Return on assets %7.512.3 61.3%  
Return on equity %12.021.9 54.8%  
Return on capital %14.633.6 43.5%  
Exports to sales %74.50 524,039.6%   
Imports to sales %24.815.1 164.6%   
Exports (fob) Rs m4,4414 111,015.0%   
Imports (cif) Rs m1,4774,237 34.9%   
Fx inflow Rs m5,298519 1,020.7%   
Fx outflow Rs m1,7728,320 21.3%   
Net fx Rs m3,525-7,801 -45.2%   
CASH FLOW
From Operations Rs m1,2741,386 92.0%  
From Investments Rs m-1,2045,010 -24.0%  
From Financial Activity Rs m-196-6,383 3.1%  
Net Cashflow Rs m-12612 -1,070.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 50.7 159.8%  
Indian inst/Mut Fund % 0.3 10.2 2.9%  
FIIs % 9.6 23.8 40.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 15.4 59.1%  
Shareholders   42,599 102,036 41.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   STRIDES SHASUN LTD  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS